The Market and Potential for Molecular Point of Care Diagnostics: Forecasts to 2018

Feb 5, 2014
245 Pages - Pub ID: KLI5201690
Share this report
Attention: There is an updated edition available for this report.
 
Online Download $995
The Market and Potential for Molecular Point of Care Diagnostics

Molecular Point of Care is a budding field in medical diagnostics. Kalorama's report, The Market and Potential for Molecular Point of Care Diagnostics, provides the most current look at this field.  

To assess the opportunity, Kalorama's report examines the molecular diagnostics business and also the point-of-care (POC) diagnostics business as they are now, and then examines at the new combination products.   A good number of companies are producing or considering molecular diagnostic platforms and assays that are made for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The business focus for most of these companies is initially on infectious disease testing, in which rapid test results generate important data that physicians can utilize in making treatment decisions.  

Included in the report is the following:
  • Company portraits for IVD Companies with POC MDX products.
  • Industry Estimates for Market Opportunity Based on Existing Markets, 2013-2018 
  • Expenditure in Molecular POC
  • Microbiology Diagnostics Opportunities 
  • Relevant Accords in Molecular
  • Purchases of Competitors with Near-Patient Solutions
  • Relevant Accords in POC 
  • Analyst Conclusions on Future Trends
POC and Moleuclar are two of the strongest growth segments of the overall IVD industry.  These once were different industry segments, but this is no longer true.  Interest has grown in developing molecular diagnostic platforms that can be used in POC settings.   Indeed, as this new industry research report from Kalorama outlines, the emerging niche of rapid molecular POC testing has attracted almost $700 million in financing in just five years.  

This report presents information derived from publicly available sources such as company reports and announcements, government reports and databases, medical organization reports, medical association announcements, and other publications. The assessment is based on the analyst’s industry knowledge combined with literature searches and discussions with industry pros and experts in the areas of POC testing, decentralized healthcare, and healthcare economics.

Almost 100 competitors involved in this industry are profiled in this report, including the following:
  • Abacus Diagnostica Oy 
  • Access Bio, Inc. 
  • Biocartis SA 
  • BioFire Diagnostics, Inc. 
  • bioMérieux sa 
  • Cepheid 
  • MBio Diagnostics, Inc. 
  • Meridian Bioscience, Inc. 
  • Micronics Inc. (A Sony Group Company) 
  • Molbio Diagnostics Pvt. Ltd. 
  • Nanosphere, Inc. 
  • NetBio, Inc. 
  • NorChip 
  • OptiGene Ltd. 
  • PositiveID Corporation 
  • QIAGEN N.V 
  • Wave 80 Biosciences 
  • Xagenic Inc.
  • and many others 
CHAPTER ONE: EXECUTIVE SUMMARY
Overview
Scope and Methodology
Market Overviews –Molecular Diagnostic and Point-of-Care Markets
Future Prospects –Molecular DIAGNOSTIC NEAR Patient/Point-of-Care Testing
CHAPTER TWO: INTRODUCTION
Evolution Towards Point-of-Care in Molecular Diagnostics – Market Drivers
Patent focused drivers
Medical/Healthcare related drivers
Technology drivers
Economic drivers
Other drivers
Overview of Companies Developing
Rapid Point-of-Care/Near-Patient Molecular Diagnostics Platforms
Point of View
CHAPTER THREE: ADVANCES IN MOLECULAR DIAGNOSTIC TECHNOLOGY
Molecular Diagnostic Technology Today
Advances and Emerging New Technologies to Make
POC Testing Possible
Advancing Molecular Diagnostic Technology for Limited Resource Settings – Non-Profit
Organizations
Bill & Melinda Gates Foundation (BMGF)
Foundation for Innovative New Diagnostics (FIND)
Program for Appropriate Technology in Health (PATH)
UNITAID
CHAPTER FOUR: DEALS – COMPANIES TARGETING MOLECULAR POINT-OF NEED/POINT-OF-CARE
Investments and Financing Agreements for Molecular Diagnostic Near-Patient/Point-of-Care
Companies
Agreements Between with Other Diagnostic Companies
Acquisitions of Molecular Diagnostic Near-Patient/Point-of-Care Companies
CHAPTER FIVE: CURRENT MARKETS
Molecular Diagnostics Market Overview
Point-of Care-Market Overview
Emerging Molecular Diagnostics Point-of-Care Market
CHAPTER SIX: MARKET OPPORTUNITIES
Healthcare Associated Infections
Influenza and Other Respiratory Tract Infections
Sexually Transmitted Diseases
Sepsis
Selected Infectious Diseases in Developing Countries
HIV/AIDS
Tuberculosis
Malaria Selected Other Diseases Found in Developing Countries
Other Infectious Diseases
Hematology/Oncology
Pharmacogenomic Tests
Risk of Thrombosis
Warfarin Sensitivity
CYP2C19 Genotyping
CHAPTER SEVEN: TECHNOLOGY DEVELOPMENTS AND PROGRESS TO DATE
Progress to Date and Current Trends
Issues and Hurdles Faced by Companies Developing Molecular Diagnostic POC Tests and
Platforms
Future Prospects
CHAPTER EIGHT: COMPANY PROFILES
Abacus Diagnostica Oy
Access Bio, Inc.
Ahram Biosystems, Inc.
Akers Biosciences, Inc.
Akonni Biosystems, Inc.
Alere Inc.
Amplino
Analytik Jena AG
Aquila Diagnostic Systems Inc.
Atlas Genetics Ltd
Atonomics A/S
Axxin
BD Diagnostics
Biocartis SA
BioFire Diagnostics, Inc.
bioMérieux sa
Canon U.S. Life Sciences
Cepheid
Coris BioConcept
Curetis AG
DestiNA Genomics Ltd.
Diagnostics for All (DFA)
Diagnostics for the Real World, Ltd.
DiaSorin S.p.A.
DiAssess Inc
DNA Electronics Ltd.
DxNA, LLC
Eiken Chemical Co., Ltd.
Enigma Diagnostics Limited
Epistem
Espira, Inc.
Focus Diagnostics, Inc.
GeneFluidics, Inc.
GenePOC Inc.
Great Basin Corporation
Hai Kang Life Corporation Limited
Hain Lifescience GmbH
HiberGene Diagnostics Ltd
iCubate, Inc.
Immunexpress Group
InstantLabs
Instrumentation Laboratory
IQuum, Inc.
Life Technologies Corporation
LiquiLume Diagnostics, Inc.
Lumora Ltd
Mast Group Ltd.
MBio Diagnostics, Inc.
Meridian Bioscience, Inc.
Mesa Tech International, Inc.
Metaara Medical Technologies Inc.
Micronics Inc. (A Sony Group Company)
Molbio Diagnostics Pvt. Ltd.
MP Biomedicals, LLC
MycroLab Diagnostics Pty Ltd.
Nanobiosym (NBS)
Nanobiosym Diagnostics (NBSDx)
NanoBioSys Inc.
NanoDetection Technology, Inc. (NDT)
NanoIVD, Inc.
Nanomix, Inc
Nanosphere, Inc.
NetBio, Inc.
NorChip
OptiGene Ltd.
PositiveID Corporation
QIAGEN N.V
QuantuMDx Group
Quidel Corporation
Rheonix Inc.
SA Scientific
Seegene, Inc.
Spartan Bioscience Inc.
STAT-Diagnostica
T2 Biosystems, Inc
Thermal Gradient, Inc.
TwistDx, Ltd. (Acquired by Alere)
Ustar Biotechnologies (Hangzhou) Ltd.
Veredus Laboratories Pte Ltd
Wave 80 Biosciences
Xagenic Inc.

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.